Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease
Hoth Therapeutics (NASDAQ: HOTH) has announced promising preclinical findings for Glial Cell Line-Derived Neurotrophic Factor (GDNF) as a potential obesity treatment. The study, using GDNF-transgenic models, demonstrated significant results in:
- Reduced body weight and fat deposition despite high-fat diet consumption
- Increased basal metabolic rate and energy expenditure
- Suppression of fat storage genes while promoting fat oxidation
- Enhanced glucose tolerance and lower serum leptin levels
- Prevention of hepatic steatosis (liver fat accumulation)
The research, conducted in partnership with the Department of Veterans Affairs, suggests GDNF could revolutionize obesity treatment by enhancing natural metabolic processes rather than restricting food intake. Hoth is exploring multiple development pathways, including recombinant protein delivery, gene therapy, and small-molecule mimetics.
Hoth Therapeutics (NASDAQ: HOTH) ha annunciato risultati preclinici promettenti per il Fattore Neurotrofico Derivato dalle Cellule Gliali (GDNF) come potenziale trattamento per l'obesità. Lo studio, utilizzando modelli transgenici di GDNF, ha dimostrato risultati significativi in:
- Riduzione del peso corporeo e della deposizione di grasso nonostante il consumo di una dieta ad alto contenuto di grassi
- Aumento del tasso metabolico basale e della spesa energetica
- Soppressione dei geni di stoccaggio dei grassi mentre si promuove l'ossidazione dei grassi
- Miglioramento della tolleranza al glucosio e livelli più bassi di leptina sierica
- Prevenzione della steatosi epatica (accumulo di grasso nel fegato)
La ricerca, condotta in collaborazione con il Dipartimento degli Affari dei Veterani, suggerisce che il GDNF potrebbe rivoluzionare il trattamento dell'obesità migliorando i processi metabolici naturali piuttosto che limitare l'assunzione di cibo. Hoth sta esplorando molteplici vie di sviluppo, tra cui la somministrazione di proteine ricombinanti, la terapia genica e i mimetici a piccole molecole.
Hoth Therapeutics (NASDAQ: HOTH) ha anunciado hallazgos preclínicos prometedores para el Factor Neurotrófico Derivado de Células Gliales (GDNF) como un posible tratamiento para la obesidad. El estudio, que utilizó modelos transgénicos de GDNF, demostró resultados significativos en:
- Reducción del peso corporal y la deposición de grasa a pesar del consumo de una dieta alta en grasas
- Aumento de la tasa metabólica basal y el gasto energético
- Supresión de los genes de almacenamiento de grasa mientras se promueve la oxidación de grasas
- Mejora de la tolerancia a la glucosa y niveles más bajos de leptina sérica
- Prevención de la esteatosis hepática (acumulación de grasa en el hígado)
La investigación, realizada en colaboración con el Departamento de Asuntos de Veteranos, sugiere que el GDNF podría revolucionar el tratamiento de la obesidad al mejorar los procesos metabólicos naturales en lugar de restringir la ingesta de alimentos. Hoth está explorando múltiples vías de desarrollo, incluyendo la entrega de proteínas recombinantes, la terapia génica y los miméticos de pequeñas moléculas.
Hoth Therapeutics (NASDAQ: HOTH)는 글리알 세포 유래 신경영양인자(GDNF)가 잠재적인 비만 치료제로서의 유망한 전임상 결과를 발표했습니다. GDNF 전이성 모델을 사용한 이 연구는 다음과 같은 중요한 결과를 보여주었습니다:
- 고지방 식이 섭취에도 불구하고 체중 및 지방 축적 감소
- 기초 대사율 및 에너지 소비 증가
- 지방 저장 유전자의 억제와 지방 산화 촉진
- 포도당 내성 향상 및 혈청 렙틴 수치 감소
- 간 지방 축적 예방
재향군인부와 협력하여 수행된 이 연구는 GDNF가 음식 섭취를 제한하는 대신 자연적인 대사 과정을 향상시켜 비만 치료를 혁신할 수 있음을 시사합니다. Hoth는 재조합 단백질 전달, 유전자 요법 및 소분자 모방체를 포함한 여러 개발 경로를 탐색하고 있습니다.
Hoth Therapeutics (NASDAQ: HOTH) a annoncé des résultats précliniques prometteurs pour le facteur neurotrophique dérivé des cellules gliales (GDNF) en tant que traitement potentiel de l'obésité. L'étude, utilisant des modèles transgéniques de GDNF, a montré des résultats significatifs dans :
- Réduction du poids corporel et des dépôts de graisse malgré une consommation de régime riche en graisses
- Augmentation du taux métabolique de base et de la dépense énergétique
- Suppression des gènes de stockage des graisses tout en favorisant l'oxydation des graisses
- Amélioration de la tolérance au glucose et niveaux de leptine sérique réduits
- Prévention de la stéatose hépatique (accumulation de graisse dans le foie)
La recherche, menée en partenariat avec le Département des Anciens Combattants, suggère que le GDNF pourrait révolutionner le traitement de l'obésité en améliorant les processus métaboliques naturels plutôt qu'en limitant l'apport alimentaire. Hoth explore plusieurs voies de développement, y compris la délivrance de protéines recombinantes, la thérapie génique et les mimétiques de petites molécules.
Hoth Therapeutics (NASDAQ: HOTH) hat vielversprechende präklinische Ergebnisse für den aus glialen Zellen abgeleiteten neurotrophen Faktor (GDNF) als potenzielle Behandlung von Fettleibigkeit bekannt gegeben. Die Studie, die GDNF-transgene Modelle verwendete, zeigte signifikante Ergebnisse in:
- Reduzierung des Körpergewichts und der Fettablagerung trotz des Konsums einer fettreichen Ernährung
- Erhöhung der Grundumsatzrate und des Energieverbrauchs
- Unterdrückung von Fettlagerungsgenen bei gleichzeitiger Förderung der Fettoxidation
- Verbesserung der Glukosetoleranz und niedrigere Serumleptinspiegel
- Prävention von Lebersteatose (Fettansammlung in der Leber)
Die Forschung, die in Zusammenarbeit mit dem Ministerium für Veteranenangelegenheiten durchgeführt wurde, deutet darauf hin, dass GDNF die Behandlung von Fettleibigkeit revolutionieren könnte, indem es natürliche Stoffwechselprozesse verbessert, anstatt die Nahrungsaufnahme zu beschränken. Hoth erkundet mehrere Entwicklungspfade, darunter die Lieferung rekombinanter Proteine, Gentherapie und kleine Molekülmimetika.
- Successful preclinical results showing GDNF's effectiveness in obesity treatment
- Multiple positive outcomes in key metabolic indicators without changing food intake
- Partnership with Department of Veterans Affairs enhances credibility
- Novel mechanism of action differentiates from existing obesity treatments
- Still in early preclinical stage, far from commercialization
- No human trial data available yet
- Multiple development pathways suggest uncertain route to market
Insights
Hoth Therapeutics' preclinical findings on GDNF (Glial Cell Line-Derived Neurotrophic Factor) represent an interesting early-stage development in obesity treatment research. The transgenic mouse model study demonstrated several notable outcomes: prevention of diet-induced obesity, enhanced fat metabolism, inhibition of adipogenesis, improved glucose regulation, and reduced fatty liver disease.
What distinguishes this approach is its unique mechanism targeting metabolic enhancement rather than appetite suppression. This differentiation from existing obesity interventions could be significant in a therapeutic area where long-term efficacy remains challenging. The partnership with the Department of Veterans Affairs potentially provides valuable research support and validation for the program.
However, investors should recognize these results are still at the preclinical stage—the earliest phase of therapeutic development. The pathway from transgenic mouse models to FDA-approved therapies is lengthy, costly, and faces significant hurdles with historically low success rates. Hoth mentions exploring multiple development approaches including recombinant protein delivery, gene therapy, and small-molecule mimetics, suggesting the optimal delivery mechanism remains undetermined.
For a micro-cap company (
- Research Demonstrates GDNF's Ability to Prevent and Reverse Obesity by Enhancing Fat Metabolism and Energy Expenditure
- Hoth is developing this therapeutic in Partnership with the Department of Veterans Affairs
Key Findings from the Study:
- Protection Against High-Fat Diet-Induced Obesity – GDNF-tg mice exhibited significantly lower body weight and reduced fat deposition despite consuming a high-fat diet.
- Enhanced Fat Burning and Energy Expenditure – GDNF increased basal metabolic rate, oxygen consumption, and carbon dioxide production, leading to higher energy expenditure without changes in food intake.
- Inhibition of Fat Cell Formation (Adipogenesis) – GDNF suppressed key genes involved in fat storage, including PPAR-γ, FASN, and SREBF1, while promoting fat oxidation pathways.
- Improved Insulin Sensitivity and Glucose Regulation – GDNF-tg mice showed enhanced glucose tolerance and lower serum leptin levels, markers of improved metabolic health.
- Reduced Fatty Liver Disease – GDNF prevented hepatic steatosis (fat accumulation in the liver), a common obesity-related complication.
"These compelling findings reinforce GDNF's potential to fundamentally alter the way we approach obesity treatment," said Robb Knie CEO of Hoth Therapeutics. "Unlike traditional weight-loss interventions that primarily focus on appetite suppression or caloric restriction, GDNF directly enhances the body's natural ability to burn fat and increase metabolic efficiency."
Key Findings from the Study:
- Protection Against High-Fat Diet-Induced Obesity – GDNF-tg mice exhibited significantly lower body weight and reduced fat deposition despite consuming a high-fat diet.
- Enhanced Fat Burning and Energy Expenditure – GDNF increased basal metabolic rate, oxygen consumption, and carbon dioxide production, leading to higher energy expenditure without changes in food intake.
- Inhibition of Fat Cell Formation (Adipogenesis) – GDNF suppressed key genes involved in fat storage, including PPAR-γ, FASN, and SREBF1, while promoting fat oxidation pathways.
- Improved Insulin Sensitivity and Glucose Regulation – GDNF-tg mice showed enhanced glucose tolerance and lower serum leptin levels, markers of improved metabolic health.
- Reduced Fatty Liver Disease – GDNF prevented hepatic steatosis (fat accumulation in the liver), a common obesity-related complication.
A Paradigm Shift in Obesity Treatment
Obesity is a major global health crisis, affecting over 650 million adults worldwide and contributing to life-threatening conditions such as type 2 diabetes, cardiovascular disease, and metabolic syndrome. Current pharmacological treatments often have limited efficacy or undesirable side effects. Hoth Therapeutics' research into GDNF suggests a novel mechanism for weight management that works by enhancing energy metabolism rather than restricting food intake.
"The data suggest that GDNF-based therapies could offer an entirely new approach to obesity treatment—one that activates the body's natural metabolic processes to burn excess fat efficiently," added Robb Knie, CEO Hoth Therapeutics. "This represents a significant advancement over current anti-obesity drugs, which often fail to maintain long-term weight loss."
Next Steps in Development
Hoth Therapeutics is actively exploring multiple pathways for the clinical translation of GDNF-based therapies, including recombinant protein delivery, gene therapy, and small-molecule mimetics that can activate the same metabolic pathways. The company plans to initiate further preclinical and clinical development efforts to bring this potential therapy closer to patients in need.
For more information on Hoth Therapeutics and its innovative pipeline, please visit www.hoththerapeutics.com
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-positive-findings-on-gdnfs-potential-as-a-game-changer-in-obesity-treatment-and-reduced-fatty-liver-disease-302391087.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What are the key findings of Hoth Therapeutics' GDNF obesity treatment study?
How does HOTH's GDNF treatment differ from traditional obesity medications?
What development stages is HOTH planning for its GDNF obesity treatment?
What specific metabolic improvements did HOTH's GDNF treatment show in the study?
How did HOTH's GDNF affect liver health in the preclinical study?
